Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sankar D Navaneethan

Showing results (61-70 of 281) with videos related to

Pageof 29
Sort By:
JAMA Network Open|February 15, 2022
Updated US Prevalence Estimates for Chronic Kidney Disease Stage and Complications Using the New Race-Free Equation to Estimate Glomerular Filtration RateCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
Journal of the American Society of Hypertension : JASH|April 23, 2010
Baroreflex stimulation: A novel treatment option for resistant hypertensionSankar D Navaneethan, Thomas E Lohmeier, John D Bisognano
Current Opinion in Nephrology and Hypertension|May 27, 2017
Emerging therapeutic options for managing diabetic kidney diseaseCarl P Walther, Adam Whaley-Connell, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|June 15, 2021
Black Race Coefficient in GFR Estimation and Prevalence of CKD-Related ComplicationsCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
Current Opinion in Nephrology and Hypertension|January 20, 2011
Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney diseaseSankar D Navaneethan, Jörgen Hegbrant, Giovanni F M Strippoli
Nephrology (Carlton, Vic.)|January 18, 2008
Meta-analysis of mycophenolate mofetil in IgA nephropathySankar D Navaneethan, Gautham Viswanathan, Giovanni F M Strippoli
Journal of the American Society of Nephrology : JASN|April 9, 2021
Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National EstimatesCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 7, 2025
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT EquationCarl P Walther, L Parker Gregg, Sankar D Navaneethan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 23, 2026
Obesity in CKD: Core Curriculum 2026Holly J Kramer, Linda-Marie Lavenburg, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|June 15, 2019
Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-AnalysisSankar D Navaneethan, Jun Shao, Jerry Buysse, et al.
Pageof 29

Showing results (61-70 of 281) with videos related to

Sort By:
Pageof 29
JAMA Network Open|February 15, 2022
Updated US Prevalence Estimates for Chronic Kidney Disease Stage and Complications Using the New Race-Free Equation to Estimate Glomerular Filtration RateCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
Journal of the American Society of Hypertension : JASH|April 23, 2010
Baroreflex stimulation: A novel treatment option for resistant hypertensionSankar D Navaneethan, Thomas E Lohmeier, John D Bisognano
Current Opinion in Nephrology and Hypertension|May 27, 2017
Emerging therapeutic options for managing diabetic kidney diseaseCarl P Walther, Adam Whaley-Connell, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|June 15, 2021
Black Race Coefficient in GFR Estimation and Prevalence of CKD-Related ComplicationsCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
Current Opinion in Nephrology and Hypertension|January 20, 2011
Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney diseaseSankar D Navaneethan, Jörgen Hegbrant, Giovanni F M Strippoli
Nephrology (Carlton, Vic.)|January 18, 2008
Meta-analysis of mycophenolate mofetil in IgA nephropathySankar D Navaneethan, Gautham Viswanathan, Giovanni F M Strippoli
Journal of the American Society of Nephrology : JASN|April 9, 2021
Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National EstimatesCarl P Walther, Wolfgang C Winkelmayer, Sankar D Navaneethan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 7, 2025
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT EquationCarl P Walther, L Parker Gregg, Sankar D Navaneethan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 23, 2026
Obesity in CKD: Core Curriculum 2026Holly J Kramer, Linda-Marie Lavenburg, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|June 15, 2019
Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-AnalysisSankar D Navaneethan, Jun Shao, Jerry Buysse, et al.
Pageof 29